Elana Gotkine is a Team Leader and journalist who writes for Medical Xpress and HealthDay News. Her work has also appeared in various publications such as Drugs.com, Wyoming Business Report, and The Herald-Palladium. Elana covers a wide range of health-related topics, including cancer research, public health guidelines, and the impact of stress on physical health.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Elana's coverage predominantly focuses on scientific and healthcare topics, including medical research, diseases, health conditions, treatments, and advancements. She frequently cites data in her articles.
Given this focus, Elana is likely to be interested in pitches from experts who can provide insights into cutting-edge medical research or breakthroughs in the treatment of various health conditions. Pitches offering access to new data or studies could also be well-received by Elana.
As she doesn't have a specific geographic focus mentioned, it's important for potential sources to ensure that their expertise aligns with the global relevance of the topics covered rather than being region-specific.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Dennis Thompson, Lori Saxena, Carolyn D. Brockington, Elana Gotkine
MONDAY, Nov. 18, 2024 (HealthDay News) -- Folks who stress-eat fatty foods like cookies, chips and ice cream might be able to protect their health with a nice cup of cocoa or green tea, a new study says.
MONDAY, Nov. 18, 2024 (HealthDay News) -- Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new Britis
By: Elana Gotkine, Mark Arredondo
MONDAY, Nov. 18, 2024 (HealthDay News) -- Patients with venous thromboembolism (VTE) initiating oral anticoagulants have an increased risk for bleeding when usi
Three years of tirzepatide also reduced risk for progression to type 2 diabetes compared with placebo
One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability
At dose of 125 mg/kg body weight, oral infigratinib results in increased annualized height velocity and z score
MONDAY, Nov. 18, 2024 (HealthDay News) -- Beta-blocker treatment can lead to a modest increase in depressive symptoms among patients who have myocardial infarct
Most issues that patients initiate in discussion omitted from notes
By: Elana Gotkine
Findings seen among patients hospitalized long term for schizophrenia
From 2022 to 2023, there was a 20 percent increase in estimated measles cases worldwide, from 8,645,000 to 10,341,000
(833) 317-6278 
.jpg?w=1200&ar=40%3A21&auto=format%2Ccompress&ogImage=true&mode=crop&enlarge=true&overlay=false&overlay_position=bottom&overlay_width=100)
